NCT03246529 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 134
- units
- Participants
- groups
- description
- Part 1 (lead-in) period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG000
- title
- BL-8040 + G-CSF Part 1
- description
- Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG001
- title
- BL-8040 + G-CSF Part 2
- description
- Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. Placebo s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG002
- title
- Placebo + G-CSF Part 2
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 4.8
- value
- 63.3
- group Id
- BG001
- spread
- 9.4
- value
- 60.4
- group Id
- BG002
- spread
- 9.6
- value
- 59.2
- group Id
- BG003
- spread
- 9.1
- value
- 60.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 48
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 86
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 12
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 114
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Not reported
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- African
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Hispanic origin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Unknown
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Not Specified
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 16
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 26
- group Id
- BG003
- value
- 90
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 17
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- title
- Spain
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 89
- title
- Bortezomib
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Cisplatin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 9
- title
- Cyclophosphamide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Daratumumab 0 - 1 2.4%
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Doxorubicin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Etoposide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Ixazomib
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 9
- title
- Kyprolis
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 97
- title
- Lenalidomide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Melphalan
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Pomalidomide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 30
- title
- Thalidomide
- description
- Treatment Indicated for Multiple Myeloma Before Study Initiation
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Treatment Indicated for Multiple Myeloma Before Study Initiation
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 41
- title
- PR (Partial Response)
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 65
- title
- VGPR (Very Good Partial Response)
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 21
- title
- CR (Complete Response)
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- title
- sCR (Stringent Complete Response)
- description
- Response criteria for the purposes of the study was defined in accordance with the International Myeloma Working Group (IMWG) Uniform Response Criteria.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- IMWG Classification at Screening
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.9
- value
- 4.6
- group Id
- BG001
- spread
- 11.1
- value
- 6.5
- group Id
- BG002
- spread
- 6.9
- value
- 6.4
- group Id
- BG003
- spread
- 9.4
- value
- 6.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Months from MM Diagnosis to Study Consent
- unit Of Measure
- months
- population Description
- Part 1: Full analysis set - all enrolled subjects. Part 2: ITT analysis set: all randomized subjects. According to the treatment group to which they were originally randomized.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 134
- units
- Participants
- groups
- description
- Part 1 (lead-in) period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG000
- title
- BL-8040 + G-CSF Part 1
- description
- Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG001
- title
- BL-8040 + G-CSF Part 2
- description
- Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. Placebo s.c. on Day 4 (and Day 6, if needed). First apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.
- id
- BG002
- title
- Placebo + G-CSF Part 2
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 4.8
- value
- 63.3
- group Id
- BG001
- spread
- 9.4
- value
- 60.4
- group Id
- BG002
- spread
- 9.6
- value
- 59.2
- group Id
- BG003
- spread
- 9.1
- value
- 60.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 48
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 86
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 12
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 114
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Not reported
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- African
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Hispanic origin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Unknown
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Not Specified
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 16
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 26
- group Id
- BG003
- value
- 90
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 17
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- title
- Spain
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 89
- title
- Bortezomib
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Cisplatin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 9
- title
- Cyclophosphamide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Daratumumab 0 - 1 2.4%
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Doxorubicin
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Etoposide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Ixazomib
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 9
- title
- Kyprolis
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 97
- title
- Lenalidomide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Melphalan
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Pomalidomide
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 30
- title
- Thalidomide
- description
- Treatment Indicated for Multiple Myeloma Before Study Initiation
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Treatment Indicated for Multiple Myeloma Before Study Initiation
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 41
- title
- PR (Partial Response)
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 65
- title
- VGPR (Very Good Partial Response)
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 21
- title
- CR (Complete Response)
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- title
- sCR (Stringent Complete Response)
- description
- Response criteria for the purposes of the study was defined in accordance with the International Myeloma Working Group (IMWG) Uniform Response Criteria.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- IMWG Classification at Screening
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.9
- value
- 4.6
- group Id
- BG001
- spread
- 11.1
- value
- 6.5
- group Id
- BG002
- spread
- 6.9
- value
- 6.4
- group Id
- BG003
- spread
- 9.4
- value
- 6.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Months from MM Diagnosis to Study Consent
- unit Of Measure
- months
- population Description
- Part 1: Full analysis set - all enrolled subjects. Part 2: ITT analysis set: all randomized subjects. According to the treatment group to which they were originally randomized.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle